WDL
IHE icon

Well Done LLC’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Well Done LLC’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,466
Closed -$295K – 87
2015
Q4 		$295K Buy
+5,466
New +$288K 0.1% 66

Other funds holding IHE

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AWA
ARS Wealth Advisors St. Petersburg, Florida $556M AUM 30.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
SFI
SPC Financial Inc Rockville, Maryland $1.28B AUM 12.6% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
EAMA
EFG Asset Management (Americas) Miami, Florida $579M AUM 24.22% 1-Year Est. Return

Well Done LLC's IHE Position: Q1 2016 in Review

Well Done LLC sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2016, closing a stake of 5,466 shares — an estimated $295K sold.

Well Done LLC first reported a position in IHE in Q4 2015 and held it in 1 quarter. The position peaked at $295K in Q4 2015. 91 funds tracked by Wall St. Rank hold IHE as of Q1 2016.

  • Well Done LLC reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2016 after selling out during the quarter.
  • Well Done LLC sold 5,466 iShares US Pharmaceuticals ETF shares in Q1 2016, an estimated $295K.
  • Well Done LLC first reported a position in iShares US Pharmaceuticals ETF in Q4 2015 and held it in 1 quarter.
  • Well Done LLC's iShares US Pharmaceuticals ETF position peaked at $295K in Q4 2015.
  • 91 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2016.

Based on Well Done LLC's 13F filing for Q1 2016, filed 27 Oct 2016.